Clinigen Group (OTCMKTS:CLIGF) Rating Increased to Buy at Zacks Investment Research

Share on StockTwits

Clinigen Group (OTCMKTS:CLIGF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday, reports. The brokerage currently has a $8.50 price objective on the stock. Zacks Investment Research‘s price objective suggests a potential upside of 10.39% from the stock’s current price.

According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “

Separately, JPMorgan Chase & Co. assumed coverage on shares of Clinigen Group in a research report on Wednesday, November 25th. They set a “neutral” rating on the stock. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $8.50.

Shares of CLIGF stock remained flat at $$7.70 on Wednesday. The stock has a market capitalization of $942.48 million, a price-to-earnings ratio of 9.51 and a beta of 0.73. The company has a 50-day moving average of $7.70 and a 200 day moving average of $8.51. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.54 and a quick ratio of 1.32. Clinigen Group has a 1 year low of $6.00 and a 1 year high of $12.30.

Clinigen Group Company Profile

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines.

Recommended Story: Capital Gains Distribution

Get a free copy of the Zacks research report on Clinigen Group (CLIGF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with's FREE daily email newsletter.